US Patent Filing

Transition to US Utility Patent:
- Theranib transitioned its initial patent titled “Medicinal compound for the inhibition of aldehyde dehydrogenase subtype 1A (ALDH1A3)” into a US Utility Patent Filing.
- This step ensures comprehensive protection of VE3, the lead ALDH1A3 inhibitor, in one of the world’s largest and most critical oncology markets.
Scope of the Patent:
- Covers the chemical structure, synthesis processes, and therapeutic application of VE3 in targeting ALDH1A3.
- Includes combination uses with other standard-of-care therapies to enhance treatment efficacy.
- Protects both the use of VE3 in addressing chemotherapy resistance and metastasis and its biomarker-driven precision approach.
Strengthening IP Portfolio:
- This filing is a significant milestone in Theranib’s global patent strategy, building on the earlier PCT filing to secure rights in multiple jurisdictions.
- Ensures exclusivity for the use of VE3 as a first-in-class therapy for ALDH1A3-expressing cancers.
Data Supporting the Filing:
- Based on robust preclinical studies showing:
  - Efficacy: Significant reduction in tumor growth and metastasis.
  - Safety: Favorable toxicology profiles with minimal off-target effects.
  - Innovation: First compound to specifically and effectively inhibit ALDH1A3 with nanomolar potency.

Market Exclusivity: Protects VE3’s commercialization potential for up to 20 years in the US market.
Investor and Partner Appeal: Demonstrates Theranib’s commitment to IP protection, reducing competitive risks and increasing valuation.
Global Expansion: Forms the foundation for filing in other key markets, such as the European Union, Canada, and Asia.
Positioning for Licensing Deals: Strengthens Theranib’s ability to negotiate licensing or acquisition agreements by securing ownership of its innovation.